Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Petra Luzna"'
Autor:
Petra Luzna, Denisa Weiser Drozdkova, Pavla Flodrova, Katarina Ondruskova, Ivo Uberall, Jiri Minarik, Zdenek Kolar, Katerina Smesny Trtkova
Publikováno v:
Biomedical Papers, Vol 167, Iss 1, Pp 43-49 (2023)
Aims. The aim of this study was to compare the expression profile of selected DNA methyltransferases and global DNA methylation status in patients with different phases of multiple myeloma (MM) . For the analysis, different cellular populations inclu
Externí odkaz:
https://doaj.org/article/da9369f7aa9d4fa88aba3942419199aa
Autor:
Katerina Smesny, Trtkova, Petra, Luzna, Denisa Weiser, Drozdkova, Katerina, Cizkova, Lucie, Janovska, Jan, Gursky, Dana, Prukova, Ivo, Frydrych, Marian, Hajduch, Jiri, Minarik
Publikováno v:
Molecular Medicine Reports. 26
Gene inactivation of the cyclin‑dependent kinase inhibitors p16
Multiple myeloma (MM) is a biologically heterogenic disease with adequate wide spectrum of chromosomal, genetic and epigenetic changes. Epigenetic modifications can influence gene activity without changing the DNA sequence. There are biochemical modi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bf9044627c4d2e48332bd426bc655b7
https://doi.org/10.9734/bpi/nfmmr/v5/11646d
https://doi.org/10.9734/bpi/nfmmr/v5/11646d
Autor:
Katerina Smesny Trtkova, Jitka Proskova, Karin Joehrer, Veronika Frybortova, Jiri Minarik, Petra Krhovska, Petra Luzna, Denisa Hrckova Drozdkova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e134-e135
Autor:
Jan Gursky, Denisa Hrckova Drozdkova, Sabina Ševčíková, Petra Luzna, Katerina Smesny Trtkova, Jiri Minarik
Publikováno v:
Blood. 132:5125-5125
Objective: Multiple myeloma (MM) is an incurable plasma-cell dyscrasia characterized by uncontrolled growth of malignant plasma cells in the bone marrow. Proteasome inhibitor bortezomib is a frontline MM drug, however acquired resistance to bortezomi
Autor:
Petra Luzna, Jan Gursky, Katerina Smesny Trtkova, Barbora Fialova, Katerina Langova, Zdenek Kolar
Publikováno v:
Oncology reports. 36(4)
The androgen receptor (AR) plays an essential role in the development and progression of prostate cancer. Castration-resistant prostate cancer (CRPC) is a consequence of androgen deprivation therapy. Unchecked CRPC followed by metastasis is lethal. S